



Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing



Jacob H. Gillis^{a,c}, Keely N. Thomas^a, Senthilkumar Manoharan^b, Mallikarjuna Panchakshari^b, Amber W. Taylor^a, David F. Miller^a, Rose T. Byrne-Nash^{a,c}, Christine Riley^a, Kathy L. Rowlen^a, Erica Dawson^{a,*}

^a InDevR Inc., Boulder, CO, USA

^b Biological E. Ltd., Hyderabad, India

^c GT Molecular, Fort Collins, CO, USA

ARTICLE INFO

Article history:

Received 23 March 2021

Received in revised form 12 July 2021

Accepted 1 September 2021

Available online 20 September 2021

Keywords:

Measles

Rubella

CCID₅₀

Identification

Antigen Quantification

MR Vaccine

Vaccine Manufacturing

Multiplexed Immunoassay

Microarray

VaxArray

ABSTRACT

Measles-containing vaccines (MCV), specifically vaccines against measles and rubella (MR), are extremely effective and critical for the eradication of measles and rubella diseases. In developed countries, vaccination rates are high and vaccines are readily available, but continued high prevalence of both diseases in developing countries and surges in measles deaths in recent years have highlighted the need to expand vaccination efforts. To meet demand for additional vaccines at a globally affordable price, it is highly desirable to streamline vaccine production thereby reducing cost and speeding up time to delivery. MR vaccine characterization currently relies on the 50% cell culture infectious dose (CCID₅₀) assay, an endpoint assay with low reproducibility that requires 10–14 days to complete. For streamlining bioprocess analysis and improving measurement precision relative to CCID₅₀, we developed the VaxArray Measles and Rubella assay kit, which is based on a multiplexed microarray immunoassay with a 5-hour time to result. Here we demonstrate vaccine-relevant sensitivity ranging from 345 to 800 IFU/mL up to 100,000 IFU/mL (infectious units per mL) and specificity that allows simultaneous analysis in bivalent vaccine samples. The assay is sensitive to antigen stability and has minimal interference from common vaccine additives. The assay exhibits high reproducibility and repeatability, with 15% CV, much lower than the typical 0.3 log₁₀ error (~65%) observed for the CCID₅₀ assay. The intact protein concentration measured by VaxArray is reasonably correlated to, but not equivalent to, CCID₅₀ infectivity measurements for harvest samples. However, the measured protein concentration exhibits equivalency to CCID₅₀ for more purified samples, including concentrated virus pools and monovalent bulks, making the assay a useful new tool for same-day analysis of vaccine samples for bioprocess development, optimization, and monitoring.

© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Measles and rubella are highly contagious viruses that cause significant morbidity and mortality. Measles virus is one of the most infectious human-borne viruses and, prior to widespread vaccination, infected > 90% of children before 15 years of age [1]. Acute measles infection is associated with fever, cough, and rash that can persist for a week [2]. Up to 6% of acute measles cases are fatal and the World Health Organization (WHO) estimates 140,000 children, most in the developing world, died from acute measles infection in 2018 [3]. Subacute sclerosing panencephalitis (SSPE), a chronic

complication of measles infection, can occur in patients up to 10 years after initial acute infection. While rare (0.007–0.011% of infections [4]), SSPE is always fatal, usually within 1 to 3 years.

Unlike measles, acute rubella infection is rarely fatal. Rubella infection during the first trimester of pregnancy is associated with severe chronic developmental disorders (congenital rubella syndrome, CRS) in the developing fetus that includes cataracts, deafness, encephalopathy, heart defects, and severe mental development disorders. When infected during the first 12 weeks of gestation, up to 80% of fetuses will develop CRS [5,6]. Prior to introduction of rubella vaccination (and in non-immunized populations), CRS occurs at a rate of 0.8–4.0 per 1000 live births [7], though this likely greatly under-reports the occurrence [8].

* Corresponding author.

E-mail address: dawson@indevr.com (E. Dawson), dawson@indevr.com (E.

Current measles vaccines are up to 99% effective, but high coverage rates of 95% or greater are necessary for elimination of measles [9–11]. Rubella vaccines have demonstrated similar efficacy [8,12,13], reducing the incidence of CRS in newborns to < 20 total per year in WHO regions with high (>90%) vaccination coverage [14].

Measles-containing vaccines (MCV) are affordable, available, and have been in use for a half-century in the developed world, but coverage in low- and middle-income countries is lacking due in part to cold-chain requirements and manufacturing costs. Several initiatives aim to enable low-cost manufacturing of measles and rubella (MR) vaccines at the quantity and cost required for widespread vaccination in the developing world [15]. Recent efforts have been highly successful, reducing the number of measles-associated deaths by 74% worldwide between 2000 and 2010 [16], but a 50% increase in measles mortality worldwide between 2016 and 2019 [16] highlights the fight is not over.

MR vaccines rely on cell-culture based assays, such as 50% Cell Culture Infectious Dose (CCID₅₀), for characterization during manufacturing, including identity, potency, and stability testing. Infectivity measurements are widely adopted and highly predictive of vaccine efficacy [17–18] but present certain limitations, as the time to result is 10–14 days and execution requires trained personnel. In addition, CCID₅₀ assays rely on subjective, discontinuous endpoint measurements and are notoriously error prone with observed variability of $\pm 0.3 \log_{10}$ infectious units per mL (50–100% variability) [19–20], resulting in costly hold times and lot rejections that can increase manufacturing costs and delay delivery of critical vaccine doses.

This work describes the development of an alternative assay for tracking antigen content, stability, and identity throughout the MR vaccine manufacturing process. We have adapted the VaxArray technology, described previously for influenza vaccines [21–24], for the evaluation of MR vaccine antigens. VaxArray assays are simple multiplexed immunoassays that use monoclonal antibodies in a glass microarray format. In addition to multiplexing, VaxArray provides a significant advantage in terms of reagent use, requiring 100x less capture antibody than ELISA. Here we demonstrate feasibility of the VaxArray technology for measuring antigen content in MR vaccines, enabling streamlined characterization at several manufacturing steps.

2. Materials and Methods

2.1. Anti-measles and rubella antibodies

Antibodies raised against measles and rubella virus-specific were obtained from numerous commercial sources, including Lifespan Bioscience (Seattle, WA), Novus Biologicals (Littleton, CO), Fitzgerald Industries International (Acton, MA), GeneTex (Irvine, CA), ViroStat Inc. (Westbrook, ME), Antibodies-Online (Aachen, Germany), MilliporeSigma (Burlington, MA), and HyTest Ltd (Turku, Finland).

2.2. VaxArray MR assay

The VaxArray Measles and Rubella (MR) assay is similar to previously-described VaxArray Influenza assays [21–24], with the slide layout, microarray layout, and detection principle depicted in Fig. 1a, b, and c, respectively. A single virus-specific monoclonal antibody against each virus is printed on the microarray (Fig. 1A) and used to capture viral antigens which are detected via a fluorescent antibody. Each VaxArray MR assay kit (VXMR-9001, InDevR Inc.) contains two microarray slides, each with 16 replicate arrays (see Fig. 1a and 1b), MR Blocking Buffer (MRBB), MR Lysis Buffer

(4x), and Wash Buffers. Prior to use, VaxArray MR slides were equilibrated at 25 °C for 30 min. Samples were prepared individually at 3x final concentration by lysing at 25 °C for 30 min in 1x PBS + 1x MR Lysis Buffer. Each sample was further diluted in MR Blocking Buffer to 1x, and 50 μ L was applied to individual arrays. Slide(s) were incubated in a humidity chamber (VX-6200, InDevR Inc.) on an orbital shaker at 65 rpm for 4 to 20 h at 25 °C. MR Blocking Buffer and antigen-specific detection label (VXMR-7634 and VXMR-7635, InDevR Inc.) was prepared and added to each array following antigen removal. Each slide was further incubated for 30 min in the humidity chamber at 65 rpm at 25 °C before subsequent, sequential washes with Wash Buffer 1, Wash Buffer 2, 70% ethanol, and water. Slides were dried and imaged using the VaxArray Imaging System (VX-6000, InDevR Inc.). Fluorescence intensities were processed using the validated VaxArray Analysis Software utilizing the algorithms of Kuck et al. [24]. When appropriate, sample concentrations were calculated against a standard curve from the same experiment.

2.3. Cell culture

Growth medium for Vero cells (CCL-81, ATCC) consisted of Medium 199 (11150059, Gibco) supplemented to 5% fetal bovine serum (A3160401, Gibco) plus 2 mM L-Glutamine (A2916801, Gibco) and 1x Penicillin-Streptomycin (15140148, Gibco). Diluent medium for Vero cells consisted of Medium 199 (11150059, Gibco) supplemented to 2% fetal bovine serum (A3160401, Gibco) plus 2 mM L-Glutamine (A2916801, Gibco) and 1x Penicillin-Streptomycin (15140148, Gibco).

Vero cells were grown in Vero growth media in adherent cell culture flasks (Nunc EasYFlask) to 80–90% confluency. Cells were collected by washing adherent cells with sterile Dulbecco's PBS (14190136, Gibco) followed by incubation for ~ 5 min with 0.25% Trypsin-EDTA (25200056, ThermoFisher). Cells were then collected, and trypsin was inactivated with an equivalent volume of supplemented growth medium.

Growth medium for Rabbit Kidney (RK13) cells (CCL-37, ATCC) consisted of Dulbecco's Minimum Essential Medium (12-614F, Lonza) supplemented to 10% fetal bovine serum (A3160401, Gibco) plus 2 mM L-Glutamine (A2916801, Gibco) and 1x Penicillin-Streptomycin (15140148, Gibco). Diluent medium for RK13 cells consisted of Dulbecco's Minimum Essential Medium (12-614F, Lonza) supplemented to 5% fetal bovine serum (A3160401, Gibco) plus 2 mM L-Glutamine (A2916801, Gibco) and 1x Penicillin-Streptomycin (15140148, Gibco).

Cell cultures RK13 cells were grown in RK13 growth media in adherent cell culture flasks (Nunc EasYFlask) to 80–90% confluency. Cells were collected by washing adherent cells with sterile Dulbecco's PBS (14190136, Gibco) followed by incubation for ~ 5 min with 0.25% Trypsin-EDTA (25200056, ThermoFisher). Cells were then collected, and trypsin was inactivated with an equivalent volume of supplemented growth medium.

2.4. Cell culture infectious dose (CCID₅₀)

Cell Culture Infectious Dose (CCID₅₀) assays were performed at InDevR Inc. and Biological E. Ltd. following Biological E. Ltd. protocols. Virus-containing samples were initially diluted in cell-line matched diluent medium and further serially diluted by 0.5 \log_{10} in diluent medium to create 12 virus dilutions. 50 μ L diluent medium was added to all wells of treated 96-well plate(s) (161093, Nunc), and 50 μ L serially diluted sample were added to each row of the plate (8 replicates each dilution). Control plates (no virus) were generated by adding an extra 50 μ L diluent medium.

Vero cells were utilized for measles virus, and RK13 cells for rubella virus. Cell cultures were started ~ 1 week prior to execut-




Fig. 1. The VaxArray antibody microarray design and layout. (a) Each VaxArray slide consists of 16 identical wells, each containing the printed microarray. (b) The microarray consists of 9 spatially segregated replicate spots of each capture antibody, where M(i) denotes an anti-measles antibody and R(i) denotes an anti-rubella antibody. (c) Viral antigen, captured by the printed monoclonal antibody, is further bound by a fluorophore-conjugated secondary detection antibody, resulting in fluorescent detection and quantification.

ing CCID₅₀. Cells were grown in a CO₂ incubator at 37 °C and 5% CO₂ to 80–90% confluency in T175 flasks, collected by trypsin release as described above, and cell concentration determined via hemocytometer. Cells were collected, centrifuged, and reconstituted in diluent medium to create 13 mL of 1.1 × 10⁵ cells/mL solution per CCID₅₀ plate. 100 µL cell solution was added to every well of every plate, including the control plate.

Plate(s) were covered and placed in CO₂ incubators at 32 °C (rubella) or 36 °C (measles). Plates were incubated for 10 days with periodic inspection under an inverted microscope. At the end of the 10-day incubation, all wells of the plate(s) were inspected for cytopathic effects. A Spearman-Kärber calculation [25,26] was applied to determine the CCID₅₀ titer of each sample.

2.5. Virus-containing samples

Three (3) lots of monovalent bulk containing live-attenuated measles CAM-70 strain, 4 lots of monovalent bulk containing live-attenuated rubella Wistar RA 27/3 strain, 3 lots of lyophilized vaccine containing measles CAM-70 and rubella Wistar RA 27/3, and 17 rubella Wistar RA 27/3-containing samples, from 2 separate lots (3 different growth conditions for one lot, and a single growth condition for the second lot), harvested at different infection times ('harvest samples'), were obtained from Biological E. Ltd. (Hyderabad, India). A separate set of 12 harvest samples containing measles Schwarz from a single lot of material but representing 3 different growth conditions were provided by Batavia Biosciences B.V. (Leiden, Netherlands).

2.6. Analytical sensitivity and linear dynamic range

Samples were lysed using MR Lysis Buffer (VXMR-6310, InDevR) for 30 min at 25 °C in a biosafety cabinet. Samples were serially diluted in MR Blocking Buffer (VXMR-6309, InDevR) to create a 13-point standard curve. Test samples at low virus concentrations were lysed and diluted in MR Blocking Buffer prior to analysis (n = 4). 50 µL of each standard was added to individual arrays on VaxArray Measles and Rubella v1.0 assay slides (VXMR-9051, InDevR), and further processed using virus-specific detection labels with slides imaged at 700 ms exposure time.

A linear regression was applied to each set of 4 adjacent standards across the 13-pt dataset with each slope and R² calculated. The upper limit of quantification (ULOQ) was defined as the highest antigen concentration analyzed that was within a 4-point fit R² > 0.95. To determine the lower limit of quantification (LLOQ),

the low-concentration test samples were quantified against the matched standard curve and the average concentration and standard deviation across 4 replicates determined. LLOQ was defined as the lowest concentration with a %CV < 25% and a % difference from expected (accuracy) < 25%.

2.7. Analytical specificity and accuracy in bivalent samples

Monovalent bulk measles CAM-70 and rubella RA 27/3 samples and bivalent mixtures of the two were prepared by serially diluting in MR Blocking Buffer, with monovalent and corresponding bivalent samples containing the same concentrations. Samples were analyzed by the VaxArray Measles and Rubella Assay as described previously. To determine specificity and accuracy of bivalent analysis, the assay response for a virus analyzed in monovalent form was compared to the same response when analyzed in the bivalent sample and the statistical difference between the two regressions compared.

2.8. Assay precision

On three days, three separate users executed the VaxArray MR assay. On each day, a bivalent mixture of measles Schwarz (harvest sample) and rubella RA 27/3 (monovalent bulk) was prepared in PBS. The highest standard was diluted in PBS, lysed, and further diluted in MR Blocking Buffer to create the standards. In addition, 3 samples (high, middle, and low concentrations) were generated in PBS, with each lysed 8 separate times before dilution in MR Blocking Buffer. 50 µL of each standard and sample replicate were added to individual microarrays and processed as described previously. The average sample concentration and standard deviation for each sample were determined (n = 8). Day-to-day results were compared for each sample, with results also normalized by their dilution factor to compare all replicates (n = 72).

2.9. Correlation and accuracy relative to CCID₅₀

Monovalent harvest samples (measles Schwarz or rubella RA 27/3) were prepared and analyzed by both VaxArray CCID₅₀ assay previously described. Seventeen (17) rubella harvest samples were analyzed, using a CCID₅₀-characterized monovalent bulk as the VaxArray calibrant. Eleven (11) measles harvest samples were analyzed. As the difference in titer for the 11 samples was small, each sample was also further diluted twice to create 33 total samples. Measles samples were then analyzed by VaxArray and CCID₅₀

using a separate harvest sample previously measured by CCID₅₀ as the VaxArray calibrant.

Separately, 5 concentrated virus pools (CVP), 3 monovalent rubella RA 27/3 bulks, and 2 monovalent measles CAM-70 bulks, all from separate manufacturing lots were analyzed by VaxArray MR and CCID₅₀. Additionally, 3 final vaccines (measles CAM-70 and rubella RA27/3) from separate lots were analyzed. A separate monovalent bulk for each virus from a different lot with known CCID₅₀ was used as the VaxArray calibrant.

2.10. Thermal degradation/stability indication

CAM-70 measles and RA 27/3 rubella monovalent bulk samples were aliquoted into separate glass vials, sealed with a rubber stopper and aluminum crimp-top, and frozen at -80 °C. 'Treated' vials were then placed in a water bath at + 60 °C for 48 h or in an incubator at + 37 °C for 24 h, after which the 'untreated' vials were removed from the freezer and allowed to equilibrate to 25 °C in a biosafety cabinet. Untreated and thermally treated materials were combined in specific ratios, and each prepared sample was lysed and analyzed by VaxArray. The assay response for each tested sample was compared to the fully intact sample and a % signal was determined. The percent signal relative to intact material was plotted against the % intact material and a linear regression was applied.

2.11. Interfering substances

Separately, solutions containing 5% sucrose (S9378, Sigma), 1.125% sodium chloride (S3014, Sigma), 6.25% sorbitol (S1876, Sigma), 1% Tween 80 (BP338, Fisher Scientific), and 2% gelatin (G1393, Sigma) were prepared (w/v) in deionized water. A bivalent mixture of measles and rubella virus was prepared and combined with each vaccine-relevant matrix, resulting in samples of virus plus 0.38% sucrose, 0.90% sodium chloride, 5% sorbitol, 0.125% Tween 80, or 1.60% gelatin. A control was prepared by diluting in PBS (P3813, Sigma). Each sample was lysed using MR Lysis Buffer for 30 min, further diluted in MR Blocking Buffer to 6x LLOQ, with each added to 4 replicate arrays. A standard curve was prepared by serially diluting the PBS-control sample in MR Blocking Buffer after lysis. All slides were processed and imaged as described previously, and samples were quantified against the relevant standard curve and the average concentration of each virus in each sample determined. A student's T-test evaluated the statistical significance of each sample relative to the control.

3. Results and discussion

3.1. Antibody pair selection

Antibodies against measles nucleoprotein and rubella E1, E2, and capsid proteins were obtained and printed on a "screening" microarray. A panel of 21 monoclonal antibodies, raised against measles (n = 9) or rubella (n = 12) were each printed in triplicate on the microarray. Antibodies were evaluated for reactivity, specificity, limit of detection, linear dynamic range, and stability indicating capabilities, with a single antibody for each virus was down-selected for inclusion in the final assay. The measles antibody targets the nucleoprotein (NP), the most abundant protein in the virus particle and to which antibodies are produced most rapidly and in high numbers [27]. The rubella antibody chosen targets the E1 surface glycoprotein, a major immunogen [28]. The exact binding epitopes of the antibodies chosen are not known.

3.2. VaxArray MR assay has broad linear dynamic ranges and vaccine-relevant limits of quantification

To assess assay linearity, monovalent measles- and rubella-containing samples were analyzed to determine the ULOQ and LLOQ of the assay for each strain analyzed. As shown in Fig. 2, the assay demonstrated good sensitivity and linearity for CAM-70 measles (Fig. 2.a), Schwarz measles (Fig. 2.b) and Wistar RA 27/3 rubella (Fig. 2.c). Fig. 2.c inset further highlights the linear response to lower-concentration dilutions of the rubella sample. Each strain showed linearity over $\geq 43x$ and resulted in LLOQ from 800 to 345 infectious units per mL, or IFU/mL (Table 1). Importantly, these LLOQ values are < 2,000 IFU/mL (3.3 log₁₀ IFU/mL) minimum required in the final vaccine [18] and are sufficient for antigen tracking throughout vaccine manufacturing.




Fig. 2. VaxArray MR assay response curves for serial dilutions of (a) measles CAM-70 strain, (b) measles Schwarz strain, and (c) rubella Wistar RA 27/3 strain. Values shown are median signal intensities, and error bars represent ± 1 standard deviation of the 9 replicate spots within the array for the relevant antibody.

Table 1
Limits of Quantification of the VaxArray Measles and Rubella Assay.

Virus	Strain	Lower Limit of Quantification [IFU/mL]	Upper Limit of Quantification [IFU/mL]	Linear Dynamic Range
Measles	CAM-70	800	100,000	125x
	Schwarz	345	50,000	145x
Rubella	Wistar RA 27/3	360	15,500	43x

3.3. VaxArray MR assay is capable of accurate, simultaneous bivalent measles and rubella analysis

To investigate the suitability of the VaxArray MR assay for bivalent analysis, measles and rubella monovalent bulk stocks were prepared and serially diluted in monovalent form as well as combined and serially diluted as a bivalent sample (same virus concentrations present in the bivalent and corresponding monovalent samples). Each sample was analyzed and the signal responses compared to determine if the presence of the off-target virus affected accurate quantification of the target virus.

As shown in Fig. 3a, when a measles-only sample is analyzed, only the measles-specific capture antibody shows a response while the signal intensity of the rubella-specific antibody is < 1.02x background. Similarly, as shown in Fig. 3b, a rubella-only sample demonstrates detection only on the rubella-specific capture antibody, with the signal on the measles-specific antibody is 1.16x background. A representative image of a bivalent analysis is shown in Fig. 3c. Direct comparison of response curves for equivalent virus concentrations in monovalent and bivalent formulations are shown in Fig. 3d and Fig. 3e. For measles, the linear regressions

through the monovalent and bivalent data series shown in Fig. 3d have similar slopes and y-intercepts. Similarly, the rubella-specific antibody demonstrated minimal difference in assay response in monovalent vs. bivalent samples (Fig. 3e). These results indicate that the analysis of one virus is not inhibited by and does not interfere with the presence of the other virus. The ability to simultaneously quantify both components in bivalent samples provides a distinct advantage, as the VaxArray MR assay does not require the anti-rubella neutralizing serum required for the CCID₅₀ assay of measles due to the concomitant growth of rubella in Vero cells.

3.4. VaxArray MR assay is compatible with common vaccine additives

It is also important to investigate potential interference from common stabilizers and excipients typically added to MR vaccine samples to improve shelf stability and assist in the freeze-drying process. To investigate potential interferents, a bivalent mixture of measles and rubella bulks was spiked into five matrices at vaccine-relevant concentrations[29].




Fig. 3. Assay response for monovalent and bivalent measles- and rubella-containing samples. In (a), an image representative of monovalent measles detection is shown. In (b), an image representative of monovalent rubella detection is shown. In (c), an image representative of bivalent measles and rubella detection is shown. In (d and e), response curves for measles and rubella in both monovalent and multivalent samples are compared, respectively. Error bars in e and f represent ± 1 standard deviation of the 9 replicate antibody spots within the array.

Measles detection accuracy was unaffected by the presence of any of the tested additives (Fig. 4.a), with all measurements being statistically equivalent to a PBS control. Rubella quantification was statistically unaffected for all matrices except sucrose (Fig. 4.b). When spiked into a solution at 0.38% sucrose, rubella detection was depressed by 15% relative to the PBS control. Due to the assay's high precision, this measurement was statistically significantly different than the PBS control ($p < 0.01$), however, was still within a typical 80–100% accuracy requirement, suggesting the assay produces accurate results in the presence of common MR vaccine additives. In addition, the assay's high sensitivity allows for significant dilution of samples prior to analysis, potentially alleviating the interference by diluting the sucrose to sufficiently low levels.

3.5. VaxArray MR assay is highly reproducible

Traditional cell culture assays, such as CCID₅₀, are subject to variability of up to 0.3 log₁₀ IFU/mL [19–20]. This translates to relative error of up to 50%–100%. These high levels of uncertainty can cause unnecessary wastage and expensive lot rejections.

Bivalent mixtures of measles- and rubella-containing samples were analyzed at low, medium, and high concentrations relative to the LDR. Eight replicates of each bivalent sample were prepared and lysed prior to VaxArray analysis. In accordance with the ICH Guideline for Validation of Analytical Procedures [30], the study was performed by three separate users on three separate days to evaluate intermediate precision.

The assay demonstrated high precision, with %CV < 20% for all tested cases on all days (Fig. 5). The average errors were $6.9 \pm 1.5\%$, $9.9 \pm 6.7\%$, and $6.5 \pm 3.3\%$ for users 1, 2, and 3, respectively, demonstrating no significant differences in the performance of the assay on different days or by different users. In addition, the error across all 72 normalized replicates was 16.2% for measles and 8.9% for rubella, demonstrating high intermediate precision and high linearity of dilution. The concentration of the 'low' test sample

was ~ 6x LLOQ, indicating the assay retains high precision even at challenging concentrations. This is a significant improvement over the imprecision often experienced with CCID₅₀, providing a route for same-day, precise measurements for appropriate applications.

3.6. VaxArray MR assay is sensitive to antigen stability

MR vaccines are characterized by their infectivity with antigen stability an important consideration for vaccine manufacturers, as conformationally folded protein is one critical driver of infectivity, immune recognition, and vaccine efficacy. Vaccine monovalent bulks containing measles or rubella virus were subjected to 60 °C for 48 h to fully denature the viral proteins. Degraded monovalent bulk was combined with intact (non-treated) monovalent bulk at various ratios and analyzed by VaxArray MR to demonstrate the ability of the assay to measure conformationally intact protein. While antigen stability is an important consideration, retention of infectivity is also a critical consideration for live-attenuated vaccines. A second experiment in which CAM-70 measles and RA 27/3 monovalent bulk virus were treated at + 37 °C for 1 day was also conducted to determine the effect on the VaxArray measurement.

The VaxArray MR assay does not detect denatured proteins, as indicated by complete loss of signal when + 60 °C heat-treated virus (0% intact (undegraded) sample) was analyzed (Fig. 6, dashed circles). As the proportion of intact sample was increased (relative to degraded sample), the assay response was linear and indicated slope of 1 and a y-intercept near 0, confirming detection of only the conformationally folded protein components in a mixture of degraded and intact sample.

When virus was heat-treated at + 37 °C, the sample containing only heat-treated virus did not demonstrate complete signal loss (Fig. 6, filled circles), but rather produced a signal of ~ 40% relative to the fully intact sample. As the portion of intact sample was increased (relative to degraded sample), the assay response remained linear, but the slope was < 1 for each virus, suggesting




Fig. 4. Accuracy of measles and rubella quantitation in the presence of common MR vaccine additives at vaccine relevant concentrations. Each sample was quantified against a standard curve prepared in PBS, with the average of 4 replicates of each sample reported for (a) measles and (b) rubella. Error bars represent ± 1 standard of the average. The asterisk (*) indicates a statistically significant difference from the PBS control with $p < 0.01$.




Fig. 5. Accuracy and precision data for high, intermediate, and low concentration samples for measles (a) and rubella (b). Individual replicate results for users 1, 2, and 3 are shown in blue, green, and black open circles, respectively. Solid black bars represent the overall average of the sample tested across all 3 days (n = 24 replicates). Error bars represent ± 1 standard deviation of the replicates (n = 24). (c) The %CV of each sample was determined across the three days/users for each sample tested for both antibodies, with all replicates normalized for dilution factor to allow a direct comparison across all 72 replicates analyzed. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 6. Results for monovalent measles (a) and rubella (b) bulk samples subjected to + 60 °C for 48 h or + 37 °C for 24 h. Mixtures with varying ratios of degraded and intact bulk were prepared and analyzed, with the signal intensity of each sample compared to that of the fully intact sample. A linear regression was applied to each set, with slopes and coefficients of regression (R²) as shown.

that exposing measles and rubella viruses to + 37 °C for 1 day does not fully denature the epitope probed by the antibodies on the microarray. In a separate study (data not shown), the same mono-

valent bulk virus samples incubated at + 37 °C for 1 day and subsequently analyzed byCCID₅₀. Both bulks demonstrated complete loss of infectivity, suggesting that protein/antigen stability as mea-

sured by VaxArray is not directly predictive of infectivity for thermally degraded samples. It is known that the infectivity of measles virus is dependent on the conformational stability of the viral proteins and integrity of the viral membrane [31], and very likely that temperature treatment affects conformation, particularly in these liquid monovalent bulk materials not stabilized with typical final vaccine excipients; however, given that the exact binding epitopes of the antibody probes utilized are not known, we cannot speculate on the underlying mechanism for the assay's difference in response from an infectivity measurement.

3.7. VaxArray MR measurements are correlated to CCID₅₀ measurements

To investigate the correlation between VaxArray and CCID₅₀, crude harvest samples for each virus were analyzed by both assays (see Methods section for details).

VaxArray measurements were generally correlated with the CCID₅₀ measurements for both viruses, with positive slopes and R² of 0.81 and 0.75 for measles and rubella, respectively (Fig. 7). However, the measured concentration is not equivalent to CCID₅₀. This result is not unexpected and is likely because the VaxArray immunoassay measures conformational protein content rather than infectious dose. In the harvest samples analyzed here, there are likely levels of free protein (not associated with intact, infectious viral particles) that vary from batch-to-batch, or within a batch as a function of harvest time or growth condition. These proteins are detected by VaxArray but would not cause CPE in a CCID₅₀ assay. In addition, if the ratio of free protein to infectious particles is inconsistent for all samples and the calibrant, it is expected that VaxArray measurements will not be identical to CCID₅₀ measurements and therefore may be used only as a rapid measure of anti-

gen content for these bioprocess samples. We note that the harvest samples utilized in this study were isolated from a single measles lot and 2 different rubella lots, and from numerous different manufacturing conditions within each lot. Based on preliminary studies (data not shown), analysis of samples from a single lot and a single condition (i.e. single standard manufacturing batch) is likely to improve the correlation.

3.8. VaxArray MR exhibits high accuracy for purified samples

To evaluate the potential use of the VaxArray MR assay with more purified downstream samples, a set of 2 monovalent measles bulks (CAM-70), and a set of 5 concentrated virus pools (CVP) and 3 monovalent rubella bulks (RA 27/3 strain, from separate manufacturing lots), were analyzed by VaxArray and CCID₅₀. In addition, 3 final vaccines from separate manufacturing lots were reconstituted, and both the measles and rubella components analyzed by VaxArray and CCID₅₀. Fully separate monovalent bulks from unique manufacturing lots with known CCID₅₀ values were used as the VaxArray calibrant.

As summarized in Table 2, the VaxArray measurements for each lot of measles monovalent bulk were only 0.16 and 0.21 log₁₀ IFU/mL different from the CCID₅₀ measurement, within the typical CCID₅₀ error of 0.30 log₁₀ IFU/mL. The measles component in final vaccines, however, produced VaxArray values that were 0.36, 0.60, and 0.40 log₁₀ IFU/mL different from CCID₅₀ (Table 2), with VaxArray > infectious dose in all cases. As previously discussed, Fig. 3 indicates that it is unlikely the rubella virus is interfering with the measles measurement, as we observe identical response curves for measles in monovalent and bivalent samples. In addition, Fig. 4 indicates that the measurement accuracy is only minimally affected by the presence of any single vaccine additive. As




Fig. 7. Correlations between CCID₅₀ and VaxArray MR for monovalent harvest samples containing measles (a) or rubella (b), with linear regression and R² shown for each dataset.

Table 2
VaxArray and CCID₅₀ measurements of the measles component of monovalent bulk and final vaccine samples

Sample Type	Monovalent Bulk		Final Vaccine		
	A	B	C	D	E
VaxArray Measurement [log ₁₀ IFU/mL]	6.83 ± 0.06	6.69 ± 0.05	5.18 ± 0.13	5.36 ± 0.08	5.28 ± 0.08
CCID ₅₀ Measurement [log ₁₀ IFU/mL]	6.99	6.90	4.82	4.76	4.88
Difference in Titer [log ₁₀ IFU/mL]	0.16	0.21	0.36	0.60	0.40
Percent Difference	2.3%	3.0%	7.5%	12.6%	8.1%

Table 3
VaxArray and CCID₅₀ measurements of the rubella component of concentrated virus pool, monovalent bulk, and final vaccine samples

Sample Type	Concentrated Virus Pool (CVP)					Monovalent Bulk					Final Vaccine					
	A	B	C	D	E	B	C	F	G	H	I	C	F	G	H	I
VaxArray Measurement [log₁₀ IFU/mL]	6.06 ± 0.06	6.27 ± 0.05	6.26 ± 0.04	5.98 ± 0.02	6.38 ± 0.04	6.15 ± 0.02	6.03 ± 0.03	6.27 ± 0.03	4.31 ± 0.18	4.36 ± 0.04	4.38 ± 0.04	4.31 ± 0.18	6.27 ± 0.03	4.31 ± 0.18	4.36 ± 0.04	4.38 ± 0.04
CCID₅₀ Measurement [log₁₀ IFU/mL]	6.11	6.24	6.24	6.07	6.30	6.15	6.13	6.11	4.34	4.26	4.22	4.34	6.11	4.34	4.26	4.22
Difference in Titer [log₁₀ IFU/mL]	0.05	0.03	0.02	0.09	0.08	0.00	0.11	0.16	0.03	0.10	0.16	0.03	0.16	0.03	0.10	0.16
Percent Difference	0.8%	0.5%	0.4%	1.5%	1.3%	0%	1.7%	2.6%	0.8%	2.4%	3.8%	0.8%	2.6%	0.8%	2.4%	3.8%

this interference testing was done by spiking single potential interferents into monovalent liquid samples, it is possible that the multiple additives in the lyophilized vaccine affect the measles measurements differently. Therefore, a previously characterized final vaccine sample may be a more appropriate calibrant for the analysis of final vaccine samples. The measles CAM-70 analyzed is also known to exhibit aggregation, so it is possible that the virus is in different states of aggregation in the monovalent bulk as compared to the final vaccine, which may affect VaxArray differently than CCID₅₀.

For rubella, the VaxArray measurements of CVP samples were within 0.05, 0.03, 0.02, 0.09, and 0.08 log₁₀ IFU/mL, and the rubella monovalent bulks were within 0.16, 0.11, and 0.00 log₁₀ IFU/mL of the CCID₅₀ measurements (Table 3) for different lots of material. Rubella in final vaccines also showed good agreement with infectious dose, with VaxArray within 0.03, 0.10, and 0.16 log₁₀ IFU/mL of CCID₅₀ (Table 3), demonstrating high accuracy compared to CCID₅₀ for all three types of samples. In addition, VaxArray demonstrated associated measurement errors between 0.02 and 0.18 log₁₀ IFU/mL (n = 2–8 replicates per sample), significantly lower than the typical 0.30 log₁₀ error of the CCID₅₀ assay.

4. Conclusion

While MR vaccines have proven to be extremely efficacious and generate long-lasting immunity, measles and rubella viruses still inflict severe and significant morbidity and mortality, especially in the developing world. More widespread vaccination is critical to eradicate these vaccine-preventable diseases. The current method for standardization of MR vaccine materials, including in-process harvest samples, monovalent bulks, and final vaccines, is the CCID₅₀ assay which is time consuming (10–14 days), presents difficulties in the analysis of multivalent samples, and suffers from irreproducibility, creating bottlenecks and costly lot rejections that drive up vaccine cost. New tools are critical to reduce the time-to-result and increase confidence in measurements.

The VaxArray MR assay leverages the proven VaxArray technology to address these hurdles. The assay is sensitive to antigen stability and is generally correlated to infectivity for harvest samples. Quantification of antigens from one virus is unaffected by the presence of antigens from the other virus and most common MR vaccine additives, which, when combined with low limits of quantification (lower than the minimum required for vaccine samples), enable measurement of both antigens in bivalent vaccine samples.

In conjunction with a pre-calibrated internal standard, the VaxArray MR assay demonstrated high accuracy relative to CCID₅₀ for purified samples including concentrated virus pools and monovalent bulks but lower accuracy with crude harvest samples. However, these crude samples spanned multiple manufacturing lots and often different growth conditions within a lot. Further analysis of a larger number of harvest samples from a single lot and single growth condition is warranted to determine if the correlation is improved. Quantification in monovalent bulks using a previously characterized monovalent bulk as the calibrant yields more accurate measurements than in a crude harvest sample, in part, because the matrix is matched. Furthermore, after crude harvest material undergoes purification and concentration steps to arrive at monovalent bulk, the ratio of infectious virions to non-infectious material is likely more consistent. And while VaxArray MR assay results for harvest samples are correlated but not equivalent to CCID₅₀ measurements, when paired with an internal standard previously calibrated by CCID₅₀, the VaxArray MR assay may still provide utility in selecting harvests for

pooling prior to purification in a fraction of the time relative to CCID₅₀.

In addition to a short time-to-result (5 h vs 2 weeks), VaxArray MR exhibited improved reproducibility and precision with overall %CV of 15%. While not likely to replace the gold standard infectivity assay used for release testing, this ~ 10-fold improvement over CCID₅₀ could alleviate a major bottleneck in the characterization and quantification of MR vaccine samples by speeding up early characterization reducing the incidence of costly lot rejections. Further work to develop a sample pre-treatment protocol to improve the correlation with CCID₅₀ harvest samples and for vaccine stability investigations would further increase the utility of the assay throughout the MR vaccine manufacturing process. While the focus of this work is on measles and rubella (MR) vaccines, future addition of mumps and varicella-zoster to the assay would broaden applicability.

Declaration of Interests

K. Rowlen and E. Dawson are InDevR Inc. stockholders. Biological E. Ltd. was provided a VaxArray Imaging System and kits used for analysis at no charge. All other authors are (or were) employed by either InDevR Inc. or Biological E. Ltd. but have no conflicts of interest.

Author Contributions

Mr. Gillis, Dr. Byrne-Nash, Dr. Dawson, and Ms. Taylor were responsible for experimental design, data interpretation. Mr. Gillis and Dr. Dawson prepared the manuscript; all authors provided edits. Mr. Gillis, Mr. Miller, Ms. Thomas, and Mr. Panchakshari executed experiments. Dr. Rowlen, Dr. Byrne-Nash, and Mr. Gillis are inventors on related intellectual property. Dr. Rowlen and Dr. Dawson provided scientific guidance and program oversight. Dr. Dawson, Dr. Rowlen, and Dr. Senthilkumar Manoharan provided technical support and manuscript review.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-004629]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. We also thank Batavia Biosciences B.V. for providing measles Schwarz harvest samples for analysis under a material transfer agreement.

References

- [1] World Health Organization. Global Measles and Rubella Strategic Plan: 2012–2020. 2012.
- [2] Measles Signs and Symptoms | CDC n.d. <https://www.cdc.gov/measles/symptoms/signs-symptoms.html> (accessed November 11, 2020).
- [3] Measles | WHO n.d. <https://www.who.int/news-room/fact-sheets/detail/measles> (accessed July 1, 2021).
- [4] Measles Complications | CDC n.d. https://www.cdc.gov/measles/symptoms/complications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmeasles%2Fabout%2Fcomplications.html (accessed November 11, 2020).
- [5] Rubella - Symptoms and causes - Mayo Clinic n.d. <https://www.mayoclinic.org/diseases-conditions/rubella/symptoms-causes/syc-20377310> (accessed November 12, 2020).
- [6] INTRODUCING RUBELLA VACCINE INTO NATIONAL IMMUNIZATION PROGRAMMES A STEP-BY-STEP GUIDE. 2015.
- [7] Congenital Rubella Syndrome Congenital Rubella Syndrome Vaccine-Preventable Diseases. 2018.
- [8] Castillo-Solórzano C, Marsigli C, Bravo-Alcántara P, Flannery B, Ruiz Matus C, Tambini G, et al. Elimination of rubella and congenital rubella syndrome in the Americas. *J Infect Dis* 2011;204(suppl_2):S571–8. <https://doi.org/10.1093/infdis/jir472>.
- [9] van Boven M, Kretzschmar M, Wallinga J, O'Neill PD, Wichmann O, Hahné S. Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. *J R Soc Interf* 2010;7(52):1537–44. <https://doi.org/10.1098/rsif.2010.0086>.
- [10] Morse D, O'shea M, Hamilton G, Soltanpoor N, Leece G, Miller E, et al. Outbreak of measles in a teenage school population: the need to immunize susceptible adolescents. *Epidemiol Infect* 1994;113(2):355–65. <https://doi.org/10.1017/S0950268800051785>.
- [11] Ramsay ME. Measles: the legacy of low vaccine coverage n.d. <https://doi.org/10.1136/archdischild-2013-304292>.
- [12] Greaves WL, Orenstein WA, Hinman AR, Nersesian WS. Clinical efficacy of rubella vaccine. *Pediatric Infect Dis* 1983;2(4):284–6.
- [13] Massad E, Azevedo-neto RS, Burattini MN, Zanetta DMT, Coutinho FAB, Yang HM, et al. Assessing the efficacy of a mixed vaccination strategy against rubella in São Paulo, Brazil. *Int J Epidemiol* 1995;24(4):842–50. <https://doi.org/10.1093/ije/24.4.842>.
- [14] Reef SE, Strebel P, Dabbagh A, Gacic-Dobo M, Cochi S. Progress toward control of rubella and prevention of congenital rubella syndrome - Worldwide, 2009. *J Infect Dis* 2011;204:S24–7. <https://doi.org/10.1093/infdis/jir155>.
- [15] Hayman B, Pagliusi S. Emerging vaccine manufacturers are innovating for the next decade. *Vaccine: X* 2020;5:100066. <https://doi.org/10.1016/j.jvax.2020.100066>.
- [16] Patel MK, Goodson JL, Alexander JP, Kretsinger K, Sodha S v., Steulet C, et al. Progress Toward Regional Measles Elimination – Worldwide, 2000–2019. *MMWR Morbidity and Mortality Weekly Report* 2020;69:1700–5. <https://doi.org/10.15585/mmwr.mm6945a6>.
- [17] Grigorov B, Rabilloud J, Lawrence P, Gerlier D, Xiang Y. Rapid titration of measles and other viruses: Optimization with determination of replication cycle length. *PLoS ONE* 2011;6(9):e24135. <https://doi.org/10.1371/journal.pone.0024135>.
- [18] WHO Technical Report Series, No. 840, Annex 3. 1994.
- [19] Pourianfar HR, Javadi A, Grollo L. A colorimetric-based accurate method for the determination of enterovirus 71 titer. *Indian J Virol* 2012;23(3):303–10. <https://doi.org/10.1007/s13337-012-0105-0>.
- [20] LaBarre DD, Lowy RJ. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. *J Virol Meth* 2001;96(2):107–26. [https://doi.org/10.1016/S0166-0934\(01\)00316-0](https://doi.org/10.1016/S0166-0934(01)00316-0).
- [21] Byrne-Nash RT, Gillis JH, Miller DF, Bueter KM, Kuck LR, Rowlen KL. A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines. *NPJ Vaccines* 2019;4(1). <https://doi.org/10.1038/s41541-019-0099-3>.
- [22] Byrne-Nash RT, Miller DF, Bueter KM, Gillis JH, Kuck LR, Rowlen KL. VaxArray potency assay for rapid assessment of “pandemic” influenza vaccines. *NPJ Vaccines* 2018;3:1–11. <https://doi.org/10.1038/s41541-018-0080-6>.
- [23] Kuck LR, Sorensen M, Matthews E, Srivastava I, Cox MMJ, Rowlen KL, et al. Titer on Chip: New Analytical Tool for Influenza Vaccine Potency Determination. *PLoS ONE* 2014;9(10):e109616. <https://doi.org/10.1371/journal.pone.0109616>.
- [24] Kuck LR, Saye S, Loob S, Roth-Eichhorn S, Byrne-Nash R, Rowlen KL. VaxArray assessment of influenza split vaccine potency and stability. *Vaccine* 2017;35(15):1918–25. <https://doi.org/10.1016/j.vaccine.2017.02.028>.
- [25] Spearman C. Review of the Method of “Right and Wrong Cases” (“Constant Stimuli”) without Gauss's Formula. *Psychol Bull* 1909;6:27–8. <https://doi.org/10.1037/h0063767>.
- [26] Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. *Naunyn-Schmiedebergs Archiv Für Experimentelle Pathologie Und Pharmakologie* 1931;162(4):480–3. <https://doi.org/10.1007/BF01863914>.
- [27] Knipe DM, Howley JM. *Field's Virology*. sixth ed. Philadelphia: Lippincott, Williams, & Wilkins; 2013.
- [28] Chaye HH, Mauracher CA, Tingle AJ, Gillam S. Cellular and Humoral Immune Responses to Rubella Virus Structural Proteins E1, E2, and C. *J Clin Microbiol* 1992;30(9):2323–9.
- [29] FDA, CBER. Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live. n.d.
- [30] ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) Guideline on Validation of Analytical Procedures: Methodology developed to complement the Parent Guideline 2005.
- [31] Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, et al. Stabilization of measles virus for vaccine formulation. *Human Vaccines* 2008;4(5):350–9.